Integral Molecular's MPA is the industry-leading technology for antibody specificity testing and is the only specificity platform under ... integrated into the drug discovery pipelines of over ...

On June 3, 2022, Sanyou Bio integrated the super-trillion-level molecule library and related cutting-edge technologies into a unified, comprehensive platform, named it "Sanyou Super-Trillion ...

comprehensive platform, named it "Sanyou Super-Trillion Innovative Antibody Drug Discovery Platform (STAL)", and officially released it to the public. STAL was designed to integrate a variety of ...

forged through a decade of relentless effort — growing from weakness to strength — gradually building a vast and advanced technological system that paves a new path for drug discovery.

Various antibody candidates ... of making in silico biologic drug discovery a reality.” Earlier this year, the German pharma company reported that its GenAI platform was able to predict the ...

Exscientia has signed up another big pharma partner for its artificial intelligence (AI) based drug discovery platform ... exclusive rights to an anti-TIGIT antibody with potential as a cancer ...

The Company is advancing CAPTN-3, a preclinical platform of conditionally-activated tri-specific antibody that engages ... potentially lead to an approved drug product is long and subject to ...

Dr. Horowitz commented, “CAPTN-3’s dual potential mechanisms of action appear to be a promising indicator of the platform’s potential safety and efficacy to treat cancer through its ...

Dr. Horowitz commented, "CAPTN-3's dual potential mechanisms of action appear to be a promising indicator of the ... and drug resistance. The Company's oncology pipeline includes CM24, NT219, and ...